PARG and myeloid sarcoma: Given the early lethality of global PARG KO mutants and off‐target effect of small inhibitors, it is important to employ PARG conditional KO and interrogate the role of PARG in neuroinflammation, neurodegeneration, and demyelination in MS and EAE models.